drug
ferric carboxymaltose
Marketedupdated 3mo agoby American Regent Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(1)
Trials studying ferric carboxymaltose
- N/AHypoferritinemia Without Anemia Among Reproductive Age Females
- phase4IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
- phase4Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
- phase4Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
- phase1Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
- phase2Intravenous Iron Metabolism in Restless Legs Syndrome
- phase2Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
- phase3Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 8, 2027
140 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Feb 15, 2028method-of-use (U-3313)US 77547021.5y
- Feb 15, 2028method-of-use (U-3313)US 77547021.5y
- Feb 15, 2028method-of-use (U-3312)US 77547021.5y
- Feb 15, 2028method-of-use (U-3312)US 77547021.5y
- Feb 5, 2027compositionUS 7612109168d
- Feb 5, 2027compositionUS 7612109168d
- Feb 5, 2027compositionUS 7612109168d
- Feb 5, 2027compositionUS 7612109168d
- Jan 8, 2027method-of-use (U-3637)US 11364260140d
- Jan 8, 2027method-of-use (U-3637)US 11364260140d
- Jan 8, 2027method-of-use (U-3637)US 11364260140d
- Jan 8, 2027method-of-use (U-3637)US 11364260140d
- Jan 8, 2027method-of-use (U-3634)US 11433091140d
- Jan 8, 2027method-of-use (U-3634)US 11433091140d
- Jan 8, 2027method-of-use (U-3634)US 11433091140d
- Jan 8, 2027method-of-use (U-3634)US 11433091140d
- Jan 8, 2027method-of-use (U-3474)US 11478502140d
- Jan 8, 2027method-of-use (U-3474)US 11478502140d
- Jan 8, 2027method-of-use (U-3474)US 11478502140d
- Jan 8, 2027method-of-use (U-3474)US 11478502140d
- Jan 8, 2027method-of-use (U-3316)US 8895612140d
- Jan 8, 2027method-of-use (U-3315)US 8895612140d
- Jan 8, 2027method-of-use (U-3315)US 8895612140d
- Jan 8, 2027method-of-use (U-3115)US 8895612140d
FDA exclusivities (4)
- May 31, 2026I-915Indication (3y)
- May 31, 2026I-915Indication (3y)
- May 31, 2026I-915Indication (3y)
- May 31, 2026I-915Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that